Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
FDA approved the first generic drug containing liraglutide in December 2024
Paired t-tests adjusted for multiple comparisons using Benjamin-Hochberg false discovery rate correction and Perseus type imputations were used for statistical analysis
Additional coverage pathways Because UHC evaluates each medication under its own clinical policy bulletin, additional FDA-approved indications can open separate coverage pathways sometimes through medical benefit rather than pharmacy benefit
US$ 20.00
US$ 20.48
US$ 28.21
US$ 21.84
US$ 25.13
US$ 26.43
US$ 22.87
US$ 25.88
US$ 23.28
US$ 26.02
US$ 24.25
US$ 29.32
